window.pageData = {"stock":{"_id":3000000024701,"name":"嘉实中证港股通创新药指数型发起式证券投资基金","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","status":"normal","indexFundFlag":1,"stockCode":"024701","tickerId":24701,"shortName":"嘉实中证港股通创新药ETF发起联接C","currency":"CNY","exchange":"jj","masterFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"inceptionDate":"2025-09-04T16:00:00.000Z","pinyin":"jszzggtcxyzsxfqszqtzjj","fundCollectionId":4000050080000,"followedNum":2,"indexId":1000000931250,"index":{"areaCode":"cn","stockType":"index","exchange":"csi","stockCode":"931250","tickerId":931250,"name":"港股通创新药","rebalancingFrequency":"semi-annually"},"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50080000","tickerId":50080000,"name":"嘉实基金管理有限公司"},"managers":[{"name":"张超梁","stockType":"fund_manager","stockCode":"db20725549","exchange":"fm","tickerId":260312196560}],"hotMetrics":{"fpr":{"stockId":3000000024701,"type":"fpr","f_cagr_p_r_fs_ssc":5894,"f_cagr_p_r_fs_ssrp":0.9976243000169693,"f_p_r_m1_ssc":5828,"f_p_r_m1_ssrp":0.9924489445683885,"f_p_r_m3_ssc":5700,"f_p_r_m3_ssrp":0.9631514300754518,"f_p_r_fys_ssc":5565,"f_p_r_fys_ssrp":0.895039539899353,"f_p_r_m6_ssc":5388,"f_p_r_m6_ssrp":0.9647299053276406},"fp":{"stockId":3000000024701,"type":"fp","last_data_date":"2026-05-18T16:00:00.000Z","f_cagr_p_r_fs":-0.2559672425846399,"f_p_r_m1":-0.1442683206983688,"f_p_r_m3":-0.1304855275443515,"f_p_r_fys":-0.060648089774303804,"f_p_r_m6":-0.15388983532084066},"ff":{"stockId":3000000024701,"type":"ff","f_fr_d":"2025-09-03T16:00:00.000Z","f_m_fr":0.005,"f_c_fr":0.001,"f_mac_fr":0.006},"f_nlacan":{"stockId":3000000024701,"type":"f_nlacan","f_nv_d":"2026-05-18T16:00:00.000Z","f_nv":0.745,"f_nv_cr":-0.004808976756612404},"f_as":{"stockId":3000000024701,"type":"f_as","f_tas":331988120.8247,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000024700,"__csrcFundId":15554,"stockCode":"024700","masterFundShortName":"嘉实中证港股通创新药指数发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":24700,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"嘉实中证港股通创新药指数发起式(024700)","lastUpdated":"2026-05-15T17:12:22.968Z","name":"嘉实中证港股通创新药指数型发起式证券投资基金","pinyin":"jszzggtcxyzsxfqszqtzjj","fundCollectionId":4000050080000,"setUpAssetScale":466193038.14,"setUpDate":"2025-09-01T16:00:00.000Z","setUpShares":466193038.14,"inceptionDate":"2025-09-04T16:00:00.000Z","__indexSourceCsi":1,"__indexSourceEastMoney":1,"followedNum":2,"indexFundFlag":1,"indexId":1000000931250}],"bondHoldings":[{"_id":"69e8fbf51398d79843004155","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024700,"stockCode":"019785","stockName":"25国债13","holdings":15000,"marketCap":1514264,"netValueRatio":0.002,"lastUpdated":"2026-04-22T16:48:53.874Z"},{"_id":"69e8fbf51398d79843004156","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024700,"stockCode":"019773","stockName":"25国债08","holdings":8000,"marketCap":810619,"netValueRatio":0.0011,"lastUpdated":"2026-04-22T16:48:53.879Z"}]},"list":[{"_id":"69e8eca51398d79843fea058","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000024700,"sao":"本基金跟踪中证港股通创新药指数，中证港股通创新药指数从港股通范围内选取50只业务涉及创新药研发以及为制药企业提供药物研究、开发和生产等服务的上市公司证券作为指数样本，以反映港股通范围内创新药上市公司证券的整体表现。本基金的投资策略为通过投资于目标ETF实现基金投资目标。　　2026年一季度中国经济实现良好开局，呈现\"稳中向好、结构优化\"态势。生产端工业增长加快，高技术产业和装备制造业表现突出，AI产业链带动效应明显。需求端固定资产投资由降转升，基建投资成为重要支撑，出口表现亮眼，在全球供应链遇阻背景下发挥\"稳定锚\"作用。价格指标出现积极变化，核心CPI和PPI均呈现改善趋势，消费者信心持续回升。政策层面保持稳健，财政政策前置发力，为经济注入动能。总体来看，一季度经济在供需改善、政策发力等多重因素推动下实现\"开门红\"，但需关注地缘政治对供应链的潜在冲击及外需不确定性。全球经济在一季度的复杂环境中展现出超预期韧性，整体呈现温和扩张与结构性分化并存的态势。人工智能领域的持续投资热潮与部分经济体的扩张性财政政策，为全球增长提供了核心支撑。然而，地缘政治冲突频发与贸易保护主义升温，导致供应链面临重塑压力，全球风险偏好反复，而且地缘冲突推升能源成本、扰动通胀预期也使得主要央行由“预期降息”转向更谨慎观察。美国增长韧性与AI投资支撑并存，就业与通胀信号分化，政策更依赖数据，降息节奏后置。欧元区延续弱复苏，内需偏弱、政策以观望为主，避免过早宽松引发通胀反复。　　本报告期内，剔除建仓期，本基金日均跟踪偏离绝对值为0.01%，年化跟踪误差为0.33%，符合基金合同约定的日均跟踪偏离绝对值不超过0.35%的限制。","lastUpdated":"2026-04-22T15:43:33.133Z","fund":{"_id":3000000024700,"__csrcFundId":15554,"stockCode":"024700","masterFundShortName":"嘉实中证港股通创新药指数发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":24700,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"嘉实中证港股通创新药指数发起式(024700)","lastUpdated":"2026-05-15T17:12:22.968Z","name":"嘉实中证港股通创新药指数型发起式证券投资基金","pinyin":"jszzggtcxyzsxfqszqtzjj","fundCollectionId":4000050080000,"setUpAssetScale":466193038.14,"setUpDate":"2025-09-01T16:00:00.000Z","setUpShares":466193038.14,"inceptionDate":"2025-09-04T16:00:00.000Z","__indexSourceCsi":1,"__indexSourceEastMoney":1,"followedNum":2,"indexFundFlag":1,"indexId":1000000931250,"managers":[{"stockCode":"db20725549","stockType":"fund_manager","exchange":"fm","tickerId":260312196560,"name":"张超梁"}]},"announcement":{"linkText":"嘉实中证港股通创新药交易型开放式指数证券投资基金发起式联接基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1482499","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed4047fea5b3eb0543dbd","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-01-21T16:00:00.000Z","stockId":3000000024700,"sao":"本基金跟踪中证港股通创新药指数，中证港股通创新药指数从港股通范围内选取50只业务涉及创新药研发以及为制药企业提供药物研究、开发和生产等服务的上市公司证券作为指数样本，以反映港股通范围内创新药上市公司证券的整体表现。本基金的投资策略为通过投资于目标ETF实现基金投资目标。　　四季度宏观经济在政策加力下呈现企稳回升的积极态势。二十届四中全会召开及增量财政政策的落地显著提振了市场信心，叠加“反内卷”政策持续深化，推动物价温和回升，供需关系边际改善。外贸方面，尽管面临外部扰动，但非美市场出口强劲支撑整体韧性，出口结构持续优化。此外，中美元首会晤达成多项共识，双边关系出现缓和迹象，进一步改善了外部环境预期与风险偏好。四季度美国经济延续韧性但增速边际放缓，呈现显著的结构性分化特征。消费支出虽受高收入群体支撑但在整体上有所走弱，制造业景气度仍处低位震荡。通胀温和回落，美联储如期推进降息进程并宣布停止缩表，政策立场整体偏鸽；但会议纪要显示内部对未来路径仍存分歧，叠加就业数据波动，市场对降息节奏的预期在“衰退交易”与“软着陆”之间反复博弈。　　报告期内，本基金仍处于6个月建仓期内。作为ETF联接基金，本基金秉承指数化被动投资策略，积极应对成份股调整、基金申购赎回等因素对指数跟踪效果带来的冲击，降低基金的跟踪误差。","lastUpdated":"2026-03-09T14:07:00.781Z","fund":{"_id":3000000024700,"__csrcFundId":15554,"stockCode":"024700","masterFundShortName":"嘉实中证港股通创新药指数发起式","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","tickerId":24700,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"嘉实中证港股通创新药指数发起式(024700)","lastUpdated":"2026-05-15T17:12:22.968Z","name":"嘉实中证港股通创新药指数型发起式证券投资基金","pinyin":"jszzggtcxyzsxfqszqtzjj","fundCollectionId":4000050080000,"setUpAssetScale":466193038.14,"setUpDate":"2025-09-01T16:00:00.000Z","setUpShares":466193038.14,"inceptionDate":"2025-09-04T16:00:00.000Z","__indexSourceCsi":1,"__indexSourceEastMoney":1,"followedNum":2,"indexFundFlag":1,"indexId":1000000931250,"managers":[{"stockCode":"db20725549","stockType":"fund_manager","exchange":"fm","tickerId":260312196560,"name":"张超梁"}]},"announcement":{"linkText":"嘉实中证港股通创新药交易型开放式指数证券投资基金发起式联接基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1451316","linkType":"PDF","source":"csrc_pdf"}}]}